

U.S.S.N. 09/732,411

Filed: December 7, 2000

AMENDMENT AND RESPONSE TO OFFICE ACTION

In the Claims

1. (presently amended twice) A method for ~~enhancing or decreasing adhesion of a target cell to a substrate~~ inhibiting binding of a cell to an integrin or glycosaminoglycan, comprising providing the ~~target cell with an adhesion modulatory peptide associated substrate~~ such that ~~adhesion of the target cell to the substrate is enhanced or decreased as compared to substrate alone wherein the target cell expresses a receptor selected from the group consisting of $\alpha 4 \beta 1$ integrins and VCAMs, wherein the peptide binds to the receptors with a peptide, wherein the peptide has a molecular weight less than about 25000 Daltons and comprises a sequence selected from the group consisting of SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14 and SEQ ID NO:15.~~

Claim 2. (presently canceled).

3. (presently amended) The method of claim 1, wherein the ~~adhesion modulatory peptide comprises a peptide which specifically inhibits adhesion of the target cell~~ is SEQ ID NO:15.

4. (presently amended) The method of claim 1, wherein the ~~adhesion modulatory peptide is selected from the group consisting of an endothelial cell adhesion modulatory peptide, a fibroblast adhesion modulatory peptide and a macrophage adhesion modulatory peptide, cell is selected from the group consisting of an endothelial cell, a fibroblast and a macrophage; and wherein the integrin is selected from the group consisting of an $\alpha 4 \beta 1$ integrin and a VCAM.~~

U.S.S.N. 09/732,411

Filed: December 7, 2000

AMENDMENT AND RESPONSE TO OFFICE ACTION

5. (presently amended) The method of claim 4, wherein the ~~adhesion modulatory peptide~~ cell is an endothelial cell ~~adhesion modulatory peptide~~.

Claim 6. (presently canceled).

7. (presently amended twice) The method of claim ~~4~~ 1, wherein the ~~adhesion modulatory peptide is a neutrophil adhesion modulatory peptide or a myofibroblast adhesion modulatory peptide~~ cell is a neutrophil or a myofibroblast.

Claims 8-10. (presently canceled).

11. (presently amended) The method of claim 1, wherein the ~~adhesion modulatory molecule inhibits binding of an adhesion receptor predominantly expressed by the target cell~~ peptide is SEQ ID NO:7 or SEQ ID NO:14 and inhibits binding of a cell to a glycosaminoglycan.

Claims 12-15. (presently canceled).

16. (presently amended) The method of claim 1, wherein the ~~target~~ cell is within a cell population.

17. (presently amended) The method of claim 1, wherein the ~~target~~ cell is within a subject.

18. (presently amended) The method of claim 1, wherein the cell is immobilized on a substrate ~~is~~ selected from the group consisting of a polyvinyl surface, a gel, collagen, hyaluronic acid, titanium and ~~PGA~~ polyglycolic acid.

19. (presently amended) The method of claim 1, ~~further comprising contacting the substrate with the adhesion modulatory peptide, forming the adhesion modulatory peptide~~

U.S.S.N. 09/732,411

Filed: December 7, 2000

AMENDMENT AND RESPONSE TO OFFICE ACTION

~~associated substrate prior to providing the cell with the substrate~~ wherein the peptide comprises

SEQ ID NO:12 and inhibits binding of melanoma cells.

Claims 20-29. (presently canceled).